Patents by Inventor Sabine Arndt
Sabine Arndt has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9689022Abstract: The invention provides methods and compositions for the rapid and sensitive detection of post-translationally modified proteins, and particularly of those with posttranslational glycosylations. The methods can be used to detect O-GlcNAc posttranslational modifications on proteins on which such modifications were undetectable using other techniques. In one embodiment, the method exploits the ability of an engine˜red mutant of ?-1,4-galactosyltransferase to selectively transfer an unnatural ketone functionality onto O-GlcNAc glycosylated proteins. Once transferred, the ketone moiety serves as a versatile handle for the attachment of biotin, thereby enabling detection of the modified protein. The approach permits the rapid visualization of proteins that are at the limits of detection using traditional methods. Further, the preferred embodiments can be used for detection of certain disease states, such as cancer, Alzheimer's disease, neurodegeneration, cardiovascular disease, and diabetes.Type: GrantFiled: December 23, 2014Date of Patent: June 27, 2017Assignee: California Institute of TechnologyInventors: Linda Hsieh-Wilson, Nelly Khidekel, Hwan-Ching Tai, Sabine Arndt
-
Publication number: 20150344932Abstract: The invention provides methods and compositions for the rapid and sensitive detection of post-translationally modified proteins, and particularly of those with posttranslational glycosylations. The methods can be used to detect O-GlcNAc posttranslational modifications on proteins on which such modifications were undetectable using other techniques. In one embodiment, the method exploits the ability of an engine˜red mutant of ?-1,4-galactosyltransferase to selectively transfer an unnatural ketone functionality onto O-GlcNAc glycosylated proteins. Once transferred, the ketone moiety serves as a versatile handle for the attachment of biotin, thereby enabling detection of the modified protein. The approach permits the rapid visualization of proteins that are at the limits of detection using traditional methods. Further, the preferred embodiments can be used for detection of certain disease states, such as cancer, Alzheimer's disease, neurodegeneration, cardiovascular disease, and diabetes.Type: ApplicationFiled: December 23, 2014Publication date: December 3, 2015Applicant: CALIFORNIA INSTITUTE OF TECHNOLOGYInventors: LINDA HSIEH-WILSON, NELLY KHIDEKEL, HWAN-CHING TAI, SABINE ARNDT
-
Patent number: 8927300Abstract: The invention provides methods and compositions for the rapid and sensitive detection of post-translationally modified proteins, and particularly of those with posttranslational glycosylations. The methods can be used to detect O-GlcNAc posttranslational modifications on proteins on which such modifications were undetectable using other techniques. In one embodiment, the method exploits the ability of an engine˜red mutant of ?-1,4-galactosyltransferase to selectively transfer an unnatural ketone functionality onto O-GlcNAc glycosylated proteins. Once transferred, the ketone moiety serves as a versatile handle for the attachment of biotin, thereby enabling detection of the modified protein. The approach permits the rapid visualization of proteins that are at the limits of detection using traditional methods. Further, the preferred embodiments can be used for detection of certain disease states, such as cancer, Alzheimer's disease, neurodegeneration, cardiovascular disease, and diabetes.Type: GrantFiled: February 22, 2013Date of Patent: January 6, 2015Assignee: California Institute of TechnologyInventors: Linda Hsieh-Wilson, Nelly Khidekel, Hwan-Ching Tai, Sabine Arndt
-
Patent number: 8691850Abstract: The present application relates to novel phenylaminothiazole derivatives, to processes for their preparation, to their use for the treatment and/or prophylaxis of diseases and to their use for preparing medicaments for the treatment and/or prophylaxis of diseases, preferably for the treatment and/or prevention of hypertension and other cardiovascular disorders.Type: GrantFiled: August 30, 2005Date of Patent: April 8, 2014Assignee: Bayer Intellectual Property GmbHInventors: Jens-Kerim Ergüden, Gunter Karig, Ulrich Rosentreter, Barbara Albrecht, Kerstin Henninger, Joachim Hütter, Nicole Diedrichs, Peter Nell, Sabine Arndt, Walter Hübsch, Andreas Knorr, Karl-Heinz Schlemmer, Dirk Brohm
-
Patent number: 8383425Abstract: The invention provides methods and compositions for the rapid and sensitive detection of post-translationally modified proteins, and particularly of those with post-translational glycosylations. The methods can be used to detect O-GlcNAc posttranslational modifications on proteins on which such modifications were undetectable using other techniques. In one embodiment, the method exploits the ability of an engineered mutant of ?-1,4-galactosyltransferase to selectively transfer an unnatural ketone functionality onto O-GlcNAc glycosylated proteins. Once transferred, the ketone moiety serves as a versatile handle for the attachment of biotin, thereby enabling detection of the modified protein. The approach permits the rapid visualization of proteins that are at the limits of detection using traditional methods. Further, the preferred embodiments can be used for detection of certain disease states, such as cancer, Alzheimer's disease, neurodegeneration, cardiovascular disease, and diabetes.Type: GrantFiled: October 21, 2010Date of Patent: February 26, 2013Assignee: California Institute of TechnologyInventors: Linda Hsieh-Wilson, Nelly Khidekel, Hwan-Ching Tai, Sabine Arndt
-
Publication number: 20110217732Abstract: The invention provides methods and compositions for the rapid and sensitive detection of post-translationally modified proteins, and particularly of those with post-translational glycosylations. The methods can be used to detect O-GlcNAc posttranslational modifications on proteins on which such modifications were undetectable using other techniques. In one embodiment, the method exploits the ability of an engineered mutant of ?-1,4-galactosyltransferase to selectively transfer an unnatural ketone functionality onto O-GlcNAc glycosylated proteins. Once transferred, the ketone moiety serves as a versatile handle for the attachment of biotin, thereby enabling detection of the modified protein. The approach permits the rapid visualization of proteins that are at the limits of detection using traditional methods. Further, the preferred embodiments can be used for detection of certain disease states, such as cancer, Alzheimer's disease, neurodegeneration, cardiovascular disease, and diabetes.Type: ApplicationFiled: October 21, 2010Publication date: September 8, 2011Applicant: CALIFORNIA INSTITUTE OF TECHNOLOGYInventors: LINDA HSIEH-WILSON, NELLY KHIDEKEL, HWAN-CHING TAI, SABINE ARNDT
-
Patent number: 7842517Abstract: The invention provides methods and compositions for the rapid and sensitive detection of post-translationally modified proteins, and particularly of those with post-translational glycosylations. The methods can be used to detect O-GlcNAc posttranslational modifications on proteins on which such modifications were undetectable using other techniques. In one embodiment, the method exploits the ability of an engineered mutant of ?-1,4-galactosyltransferase to selectively transfer an unnatural ketone functionality onto O-GlcNAc glycosylated proteins. Once transferred, the ketone moiety serves as a versatile handle for the attachment of biotin, thereby enabling detection of the modified protein. The approach permits the rapid visualization of proteins that are at the limits of detection using traditional methods. Further, the preferred embodiments can be used for detection of certain disease states, such as cancer, Alzheimer's disease, neurodegeneration, cardiovascular disease, and diabetes.Type: GrantFiled: June 15, 2007Date of Patent: November 30, 2010Assignee: California Institute of TechnologyInventors: Linda Hseih-Wilson, Nelly Khidekel, Hwan-Ching Tai, Sabine Arndt
-
Publication number: 20100041646Abstract: The present application relates to novel 1,4-phenylene-bis-oxazolidine derivatives, to processes for their preparation, to their use for the treatment and/or prophylaxis of diseases and also to their use for preparing medicaments for the treatment and/or prophylaxis of diseases, in particular thromboembolic disorders.Type: ApplicationFiled: October 20, 2006Publication date: February 18, 2010Applicant: BAYER HEALTHCARE AGInventors: Susanne Rohrig, Jens Pohlmann, Sabine Arndt, Mario Jeske, Metin Akbaba, Elisabeth Perzborn, Christoph Gerdes, Karl-Heinz Schlemmer
-
Publication number: 20080312424Abstract: The invention provides methods and compositions for the rapid and sensitive detection of post-translationally modified proteins, and particularly of those with post-translational glycosylations. The methods can be used to detect O-GlcNAc posttranslational modifications on proteins on which such modifications were undetectable using other techniques. In one embodiment, the method exploits the ability of an engineered mutant of ?-1,4-galactosyltransferase to selectively transfer an unnatural ketone functionality onto O-GlcNAc glycosylated proteins. Once transferred, the ketone moiety serves as a versatile handle for the attachment of biotin, thereby enabling detection of the modified protein. The approach permits the rapid visualization of proteins that are at the limits of detection using traditional methods. Further, the preferred embodiments can be used for detection of certain disease states, such as cancer, Alzheimer's disease, neurodegeneration, cardiovascular disease, and diabetes.Type: ApplicationFiled: June 15, 2007Publication date: December 18, 2008Applicant: INVITROGEN CORPORATIONInventors: Linda Hseih-Wilson, Nelly Khidekel, Hwan-Ching Tai, Sabine Arndt
-
Publication number: 20080269300Abstract: The present application relates to novel phenylaminothiazole derivatives, to processes for their preparation, to their use for the treatment and/or prophylaxis of diseases and to their use for preparing medicaments for the treatment and/or prophylaxis of diseases, preferably for the treatment and/or prevention of hypertension and other cardiovascular disorders.Type: ApplicationFiled: August 30, 2005Publication date: October 30, 2008Applicant: Bayer HealthCare AGInventors: Jens-Kerim Erguden, Gunter Karig, Ulrich Rosentreter, Barbara Albrecht, Kerstin Henninger, Joachim Hutter, Nicole Diedrichs, Peter Nell, Sabine Arndt, Walter Hubsch, Andreas Knorr, Karl-Heinz Schlemmer, Dirk Brohm
-
Publication number: 20080214533Abstract: The invention relates to novel cyclic iminocarbamates of formula (I), wherein R1, R2, R3, A, Z, and n have the meanings recited in the description, to a method for the production thereof, to pharmaceutical compositions containing such materials, and to methods for the treatment and/or prophylaxis of thromboembolic diseases using them.Type: ApplicationFiled: November 22, 2005Publication date: September 4, 2008Applicant: BAYER HEALTHCARE AGInventors: Susanne Rohrig, Jens Pohlmann, Sabine Arndt, Mario Jeske, Metin Akbaba, Elisabeth Perzborn, Christoph Gerdes, Karl-Heinz Schlemmer, Arounarith Tuch, Mario Lobell, Peter Nell, Nils Burkhardt
-
Patent number: 7332355Abstract: The invention provides methods and compositions for the rapid and sensitive detection of post-translationally modified proteins, and particularly of those with post-translational glycosylations. The methods can be used to detect O-GlcNAc post-translational modifications on proteins on which such modifications were undetectable using other techniques. In one embodiment, the method exploits the ability of an engineered mutant of ?-1,4-galactosyltransferase to selectively transfer an unnatural ketone functionality onto O-GlcNAc glycosylated proteins. Once transferred, the ketone moiety serves as a versatile handle for the attachment of biotin, thereby enabling detection of the modified protein. The approach permits the rapid visualization of proteins that are at the limits of detection using traditional methods. Further, the preferred embodiments can be used for detection of certain disease states, such as cancer, Alzheimer's disease, neurodegeneration, cardiovascular disease, and diabetes.Type: GrantFiled: November 17, 2004Date of Patent: February 19, 2008Assignee: California Institute of TechnologyInventors: Linda Hsieh-Wilson, Nelly Khidekel, Hwan-Ching Tai, Sabine Arndt
-
Publication number: 20060287315Abstract: The present invention relates to novel pyridinedicarboxamides, to processes for their preparation, to their use for the treatment and/or prophylaxis of diseases and also to their use for preparing medicaments for the treatment and/or prophylaxis of diseases, in particular thromboembolic disorders.Type: ApplicationFiled: December 8, 2005Publication date: December 21, 2006Applicant: Bayer HealthCare AGInventors: Susanne Rohrig, Mario Jeske, Metin Akbaba, Ulrich Rosentreter, Stephen Boyer, Karin Fischer, Jens Pohlmann, Arounarith Tuch, Elisabeth Perzborn, Christoph Gerdes, Karl-Heinz Schlemmer, Nils Burkhardt, Swen Allerheiligen, Peter Nell, Sabine Arndt, Mario Lobell
-
Publication number: 20050130235Abstract: The invention provides methods and compositions for the rapid and sensitive detection of post-translationally modified proteins, and particularly of those with post-translational glycosylations. The methods can be used to detect O-GlcNAc posttranslational modifications on proteins on which such modifications were undetectable using other techniques. In one embodiment, the method exploits the ability of an engineered mutant of ?-1,4-galactosyltransferase to selectively transfer an unnatural ketone functionality onto O-GlcNAc glycosylated proteins. Once transferred, the ketone moiety serves as a versatile handle for the attachment of biotin, thereby enabling detection of the modified protein. The approach permits the rapid visualization of proteins that are at the limits of detection using traditional methods. Further, the preferred embodiments can be used for detection of certain disease states, such as cancer, Alzheimer's disease, neurodegeneration, cardiovascular disease, and diabetes.Type: ApplicationFiled: November 17, 2004Publication date: June 16, 2005Inventors: Linda Hsieh-Wilson, Nelly Khidekel, Hwan-Ching Tai, Sabine Arndt